Lithium Carbonate and Zuclopenthixol: Interaction Details
AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Lithium Carbonate
Zuclopenthixol
No brand names on record
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
What happens
Weakness, dyskinesias, increased extrapyramidal symptoms, encephalopathy, and brain damage
Interaction Deep Dive
An encephalopathic syndrome followed by irreversible brain damage has occurred in a few patients treated with lithium plus a dopamine-2 antagonist, particularly haloperidol. A causal relationship between these events and the concomitant use of a dopamine-2 antagonist and lithium has not been established1. Coadministration of lithium and a number of antipsychotic drugs has caused a wide variety of encephalopathic symptoms, brain damage, extrapyramidal symptoms, and dyskinesias in isolated case reports. In most cases, these effects have occurred with therapeutic lithium levels 234. However, many series and trials have reported using such combinations with no severe adverse consequences 5. The mechanism is not fully understood, but chronic lithium treatment decreases neostriatal dopaminergic activity, probably through a direct action on the G protein and the capacity of the G proteins, once activated, to stimulate adenyl cyclase 6. Hyperglycemic reactions have also occurred during combined phenothiazine and lithium use 7.
Why it happens (mechanism)
Unknown
Literature reports
7 reports — tap to read
a) Concomitant haloperidol and lithium therapy has resulted in symptoms of encephalopathy, confusion, extrapyramidal symptoms, and fever in several patients with mania 8910. Irreversible neurological injuries have been reported 1112.
b) Seizures, encephalopathy, delirium, and abnormal EEG occurred in four patients during combined lithium and thioridazine therapy. Serum lithium levels were below 1 mEq/L at the time of the toxic reaction in all cases. All patients had previously tolerated lithium in combination with another phenothiazine. Three of these patients developed symptoms within eight days of initiating combination therapy 13.
c) The addition of lithium to neuroleptic therapy exacerbated extrapyramidal symptoms (EPS) in a small study. The patients had received at least five days of treatment with either oral thiothixene, haloperidol, or fluPHENAZine in mean doses of 607.5 chlorproMAZINE equivalents prior to initiation of the lithium and were experiencing drug-induced extrapyramidal symptoms. Oral lithium was added when clinically indicated in sufficient doses to achieve a therapeutic serum concentration. The maximum levels attained were 0.65 to 1.27 mEq/L. The EPS ratings increased in all ten patients following the addition of lithium. However, only three patients developed marked symptoms and no patient developed lithium toxicity. Significantly increased symptoms included gait, shoulder shaking, elbow rigidity, and tremor 4.
d) Ten patients treated with cloZAPine and lithium were studied. Of the ten patients, four experienced significant neurologic effects, including jerking of limbs, facial spasms and tics, tremor of hands and arms, tongue twitching, and stumbling gait. One of these also experienced delirium. These effects reversed when lithium was discontinued or given at a lower dose. On rechallenge, one of two patients suffered recurrence of symptoms. By keeping serum lithium no greater than 0.5 mEq/L, cloZAPine could be safely coadministered 14.
e) ChlorproMAZINE serum levels can be significantly reduced in the presence of lithium treatment. If used concurrently, abrupt cessation of lithium may result in rebound elevation of chlorproMAZINE levels, resulting in chlorproMAZINE toxicity. In patients on a lithium-chlorproMAZINE combination, abrupt withdrawal of the lithium may precipitate chlorproMAZINE cardiotoxicity. In this report, such toxicity was manifested as sudden ventricular fibrillation associated with prolongation of the QTc interval. Hypotension and EPS are also possible in this situation 15.
f) However, other data do not support that such adverse events are frequent or indeed causally related to combination therapy. Combination of dopamine antagonist antipsychotic drugs and lithium have been used successfully in many patients with manic-depressive illness. It has been proposed that the interaction may only become significant with very high doses of one or both drugs or with failure to discontinue dosing in the presence of toxic symptoms 16.
g) A 69-year-old patient with oxygen-dependent chronic obstructive pulmonary disorder and a 25-year history of bipolar disorder was started on risperiDONE 3 mg for the treatment of new-onset auditory and visual hallucinations. She had also been maintained on a regimen of lithium (450 mg daily) for more than 10 years. In addition, she was given amantadine (100 mg twice daily) for tremor. Three weeks after the start of risperiDONE, the patient experienced a decline in mental status in addition to dizziness, worsening tremors, nausea and vomiting, polyuria, depression, and visual and auditory hallucinations. She was then admitted to the hospital for delirium. Her lithium serum level was 1.36 mEq/L at the time of the admission. All medications were discontinued. Although her lithium level decreased to 0.41 mEq/L, she continued to experience profound delirium, tremors, lethargy, and hallucinations for almost one week. After she started to respond to commands, she was restarted on lithium (300 mg at bedtime) because of the onset of mild hypomania. Five days later, she was discharged with a regimen of lithium and low-dose LORazepam for treatment of insomnia. It is suggested that delirium could have been caused by the concurrent use of lithium and risperiDONE. Other factors could also have caused delirium, such as the patient's serum lithium level and the underlying pulmonary pathology. In addition, amantadine, which facilitates the release of presynaptic DOPamine and has a mild anticholinergic effect, may have contributed 17.
Common questions
Can I take Lithium Carbonate and Zuclopenthixol together?
Weakness, dyskinesias, increased extrapyramidal symptoms, encephalopathy, and brain damage Always confirm with your pharmacist or prescriber before making any change.
How serious is the Lithium Carbonate and Zuclopenthixol interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "delayed". Effects tend to build up gradually over days to weeks.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
From our Q&A
Real reader questions about these medications, each personally answered by our pharmacist:
Questions for your pharmacist
- Does my dose of Lithium Carbonate or Zuclopenthixol need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (17)
- Product Information: LITHOBID(R) slow-release oral tablets, lithium carbonate slow-release oral tablets. JDS Pharmaceuticals,LLC, New York, NY, 2005.
- Amdisen A: Lithium and drug interactions. Drugs 1982; 24:133-139. PubMed
- Prakash R: Lithium-haloperidol combination and brain damage (letter). Lancet 1982; 1:1468-1469. PubMed
- Addonizio G, Roth SD, Stokes PE, et al: Increased extrapyramidal symptoms with addition of lithium to neuroleptics. J Nerv Ment Dis 1988; 176:682-685. DOI
- Goldney RD & Spence ND: Safety of the combination of lithium and neuroleptic drugs. Am J Psychiatry 1986; 143:882-884. PubMed
- Carli M, Anand-Srivastava MB, Molina-Holgado E, et al: Effects of chronic lithium treatments on central dopaminergic receptor systems: G proteins as possible targets. Neurochem Int 1994; 24:13-22. PubMed
- Zall H, Therman PG, & Myers JM: Lithium carbonate: a clinical study. Am J Psychiatry 1968; 125:549-555. DOI
- Cohen WJ & Cohen NH: Lithium carbonate, haloperidol and irreversible brain damage. JAMA 1974; 230:1283-1287. DOI
- Loudon JB & Waring H: Toxic reactions to lithium and haloperidol (letter). Lancet 1976; 2:1088. PubMed
- Thomas CJ: Brain damage with lithium/haloperidol (letter). Br J Psychiatry 1979; 134:552. DOI
- Sandyk R & Hurwitz MD: Toxic irreversible encephalopathy induced by lithium carbonate and haloperidol. S Afr Med J 1983; 65:875-876.
- Keitner GI & Rahman S: Reversible neurotoxicity with combined lithium-haloperidol administration. J Clin Psychopharmacol 1984; 4:104-105. PubMed
- Spring GK: Neurotoxicity with the combined use of lithium and thioridazine. J Clin Psychiatry 1979; 40:135-138.
- Blake LM, Marks RC, & Luchins DJ: Reversible neurologic symptoms with clozapine and lithium. J Clin Psychopharmacol 1992; 12:297-299. DOI
- Stevenson RN, Blanshard C, & Patterson DLH: Ventricular fibrillation due to lithium withdrawal - an interaction with chlorpromazine?. Postgrad Med J 1989; 65:936-938. PubMed
- Miller F & Menninger J: Correlation of neuroleptic dose and neurotoxicity in patients given lithium and a neuroleptic. Hosp Comm Psychiatr 1987; 38:1219-1221. PubMed
- Chen B & Cardasis W: Delirium induced by lithium and risperidone combination (letter). Am J Psychiatry 1996; 153:1233-1234. PubMed
Keep reading about Lithium Carbonate
Keep reading about Zuclopenthixol
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist